Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma

Fig. 2

Study design. aPatients who enrol in the extension study on the same day as the end-of-treatment visit in SOURCE will not attend follow-up visits at week 54 and week 60. OCS, oral corticosteroids; Q4W, every 4 weeks; s.c., subcutaneous

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us